RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
WMGYX
Price
$29.78
Change
-$0.28 (-0.93%)
Updated
Sep 20 closing price
Ad is loading...

RPTIX vs WMGYX

Header iconRPTIX vs WMGYX Comparison
Open Charts RPTIX vs WMGYXBanner chart's image
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
Delaware Ivy Mid Cap Growth Y
Price$29.78
Change-$0.28 (-0.93%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RPTIX vs WMGYX Comparison Chart
Loading...
VS
RPTIX vs. WMGYX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPTIX is a StrongBuy and WMGYX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. WMGYX (6.7B). RPTIX pays higher dividends than WMGYX: RPTIX (0.18) vs WMGYX (0.00). RPTIX was incepted earlier than WMGYX: RPTIX (9 years) vs WMGYX (24 years). WMGYX is a more actively managed with annual turnover of: 23.00 vs. RPTIX (21.70). WMGYX has a lower initial minimum investment than RPTIX: WMGYX (0) vs RPTIX (500000). RPTIX annual gain was more profitable for investors over the last year : 14.81 vs. WMGYX (13.10). RPTIX return over 5 years is better than : 15.09 vs. WMGYX (6.21).
RPTIXWMGYXRPTIX / WMGYX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence9 years24 years-
Gain YTD9.1274.970184%
Front LoadN/AN/A-
Min. Initial Investment5000000-
Min. Initial Investment IRAN/AN/A-
Net Assets31.4B6.7B469%
Annual Yield % from dividends0.180.00-
Returns for 1 year14.8113.10113%
Returns for 3 years-13.57-32.2642%
Returns for 5 years15.096.21243%
Returns for 10 yearsN/A21.85-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp